Stephanie Seidman has decades of experience providing strategic counsel on the development and commercialization of patent portfolios for the biopharma industry. She has drafted and prosecuted hundreds of pharmaceutical, biotechnical, and chemical patents, notably patent portfolios involving complex technologies. Her expertise includes molecular biology, including viral vectors and therapeutic viruses, therapeutic proteins, small molecules, chemical processes, immunology, screening, stem cells, immunotherapies, and diagnostics. Her work includes patent prosecution, focusing on early-stage patenting strategies; freedom-to-operate analyses; non-infringement and validity analyses; and IP due diligence work in financing and acquisitions.

Stephanie is recognized for her representation of emerging and developing companies, including private and public companies in the biotech and pharmaceutical industries. Her prior experience includes three decades in private practice and several years as a patent examiner for the U.S. Patent and Trademark Office. She also was a postdoctoral staff fellow at the National Institutes of Health.

Honors & Awards

  • Chambers USA: IP – Patent Prosecution, California (2016-Present)
  • IAM Patent 1000: Prosecution, California (2014-Present)
  • Legal 500: Life Sciences (2016-2017, 2023)
  • The Best Lawyers in America: Biotechnology Law (2010-Present)